The Oasis Health Journal · Submitted August 2, 2026 · 3:01 PM EDT
By June Mackerel · Edited by Colette Ward
The phosphatidic acid muscle supplement industry rests on a single elegant premise: that this particular phospholipid activates mTOR, the mechanistic target of rapamycin, which governs protein synthesis in muscle tissue. The promise is that one may bypass the usual requirement for leucine and other branched-chain amino acids and instead signal growth through a lipid, which sounds rather like finding a back door into a locked house. One imagines the house is quite surprised.
The mechanism is said to involve direct binding to the mTOR complex, which is quite specific if true, and also the sort of claim one hears at a supplement trade show from a man wearing a very tight polo shirt.
The question, of course, is whether it works in a person who lifts weights and would like larger muscles.
What the Phosphatidic Acid mTOR Research Actually Measured
The bulk of the human literature on phosphatidic acid for muscle consists of studies that measured signaling markers rather than muscle mass. Researchers have reported increases in phosphorylated mTOR and its downstream targets, p70S6K and 4E-BP1, in resistance-trained men who consumed phosphatidic acid post-workout. The effect size, where quantified, has been modest.
One imagines the participants were rather hopeful.
The studies that did measure muscle outcomes have produced inconsistent results, which is a polite way of saying some showed an effect and others did not. Sample sizes have been small. One trial involved twelve people. Another involved sixteen. These are not the sort of numbers that inspire great confidence, particularly when one is being asked to purchase a lipid at the sort of price normally reserved for small electronics.
It is also worth noting that phosphatidic acid is not a single compound but a class of lipids with varying fatty acid chains, and the supplement industry does not always specify which version is in the bottle. One suspects this is not an oversight. One suspects this very strongly indeed.
The Case of the Quite Ambitious Workout
A 2026 case report in Cureus describes a twenty-three-year-old physically active man who presented to hospital with severe myalgia, muscle weakness, fever, and dark brown urine following a resistance training session that lasted more than four hours.
Four hours is a long time to lift weights. It is a long time to do nearly anything.
His creatine kinase level was measured at greater than one hundred and twenty thousand units per litre. The normal upper limit is approximately one hundred and seventy units per litre, so this represents what one might call a departure from baseline.
The patient had been taking a rather comprehensive supplement regimen: creatine at five grams daily, beta-alanine, citrulline malate at ten grams, phosphatidic acid supplement at one point five grams, beta-ecdysterone, protein powder, vitamins, and what the authors describe, with admirable vagueness, as 'other micronutrients.' One does wonder what qualifies as 'other' when the list already includes beta-ecdysterone.
He was treated with intensive intravenous fluids and improved over ten days without developing acute kidney injury, which is fortunate. His liver enzymes were also elevated, though not to the degree one might expect if this were a primary hepatic event. The authors note that it is not possible to determine which supplement, if any, contributed to the exercise-induced rhabdomyolysis described in the report, and one rather suspects the four-hour training session may have been the more significant variable.
A modest inconvenience, then, rather than a catastrophe.
The point, however, is that phosphatidic acid for resistance trained athletes is being consumed in combination with other ergogenic supplements, often in doses that have not been studied in combination, by people who are pushing their musculature quite hard. The safety profile under those conditions is not well characterised, which is the sort of phrase one uses when the actual phrase would be 'we have no idea.'
The Lipid Metabolism Context Nobody Asked For
Phosphatidic acid is also a structural phospholipid involved in membrane biogenesis, lipid droplet dynamics, and various signaling pathways unrelated to muscle. A 2026 review in Signal Transduction and Targeted Therapy discusses the role of lipid metabolism in immune cell function, noting that lipids regulate proliferation, differentiation, and activation across multiple cell types. None of this has anything to do with your biceps, but it does suggest that consuming a signaling lipid might have effects beyond the ones advertised on the tub.
Another 2026 review in RSC Chemical Biology describes lipid droplets as 'highly dynamic hubs that integrate lipid storage with cellular and systemic metabolic regulation.' The authors were discussing obesity and liver disease, but the principle holds: lipids do many things, and giving your body more of one lipid does not guarantee it will use that lipid for the thing you had in mind. Your body has its own agenda, and that agenda may not align with your fitness goals.
The phosphatidic acid mTOR activator supplement industry has focused exclusively on the mTOR angle, which is understandable from a marketing perspective but perhaps not from a biochemistry one.
Whether One Ought to Take It
The evidence for phosphatidic acid as a muscle building supplement is not zero, but it is not robust either. The studies that measured actual muscle showed small effects or no effects. The studies that showed signaling changes did not measure muscle, which is rather like proving the doorbell works without checking whether anyone is home.
One person ended up in hospital, though it is not clear the phosphatidic acid was to blame.
If you are taking phosphatidic acid post workout, you are probably also taking creatine, protein, and several other things, and it becomes quite difficult to isolate the contribution of any single ingredient. The dose most commonly studied is seven hundred and fifty milligrams, taken twice daily. The case report involved one point five grams daily, which is within that range, so it is not as though the hospitalised man was engaged in reckless experimentation. He was, one assumes, following the label.
One suspects the four-hour workout was the larger issue.
The supplement is expensive relative to protein powder, which has the advantage of containing actual building blocks for muscle rather than a signaling lipid. Whether the signaling justifies the cost is a question each person must answer for themselves, ideally after reading the studies and noting the sample sizes, which are not large.
I am not in a position to tell you what to do, but I am in a position to tell you that the research is thin, the mechanism is plausible but unproven in humans at scale, and one man's creatine kinase reached levels that required ten days of intravenous fluids. A modest inconvenience, then, rather than a catastrophe.
This article is education and reporting on published research. It is not medical advice, and nothing here is intended to diagnose, treat, cure or prevent any disease. Talk to your own clinician about your own situation.
Sources
- Sterol regulatory element‑binding proteins: Master regulators of lipid metabolic reprogramming in cancer and emerging therapeutic targets (Review), Oncology reports (2026).
- Lipid transfer proteins and PI4KIIα initiate nuclear p53-phosphoinositide signaling, The Journal of biological chemistry (2026).
- IQGAP3, the overlooked oncogenic twin of IQGAP1: mapping its interactome and functional roles across cellular signaling and cancer, Cell communication and signaling : CCS (2026).
- Lipid droplet dynamics in metabolic regulation, RSC chemical biology (2026).
- Exercise-Induced Rhabdomyolysis With Supplements (Creatine, β-Alanine, Citrulline Malate, and β-Ecdysterone), Cureus (2026).
- Restoring Mitochondrial Homeostasis: Therapeutic Strategies for Metabolic Dysfunction-Associated Fatty Liver Disease, International journal of molecular sciences (2026).
- Lipid metabolism in homeostasis and disease, Signal transduction and targeted therapy (2026).
Leave a comment